IQVIA Holdings Inc. (NYSE:IQV) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• IQVIA Holdings Inc. has been rated as a "Moderate Buy" by analysts, with 18 out of 24 research firms issuing buy ratings and an average price target of $230.32.
• Insider trading activity saw notable sales, with Keriann Cherofsky selling 549 shares and Eric Sherbet selling 5,800 shares on the same day, reflecting a combined decrease in ownership of over 15%.
• The company's recent earnings report showed a quarterly EPS of $2.81, surpassing estimates and marking a 5.3% year-over-year revenue increase to $4.02 billion.

Shares of IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the twenty-four research firms that are presently covering the stock, MarketBeat.com reports. Six research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $230.3182.

IQV has been the subject of several recent research reports. Barclays upped their target price on IQVIA from $185.00 to $200.00 and gave the company an "equal weight" rating in a report on Thursday. UBS Group upped their target price on IQVIA from $185.00 to $225.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Mizuho upped their target price on IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a report on Friday, July 25th. Truist Financial boosted their price objective on IQVIA from $209.00 to $235.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. Finally, William Blair reiterated an "outperform" rating on shares of IQVIA in a research report on Wednesday, July 23rd.

Insider Activity at IQVIA

In other news, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the transaction, the insider directly owned 2,910 shares in the company, valued at approximately $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the transaction, the insider owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.60% of the company's stock.

Hedge Funds Weigh In On IQVIA

Several hedge funds and other institutional investors have recently made changes to their positions in IQV. Everpar Advisors LLC lifted its position in IQVIA by 4.6% in the second quarter. Everpar Advisors LLC now owns 1,404 shares of the medical research company's stock worth $221,000 after purchasing an additional 62 shares during the period. Private Trust Co. NA lifted its position in IQVIA by 12.5% in the second quarter. Private Trust Co. NA now owns 603 shares of the medical research company's stock worth $95,000 after purchasing an additional 67 shares during the period. Ballentine Partners LLC lifted its position in IQVIA by 4.9% in the first quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company's stock worth $260,000 after purchasing an additional 69 shares during the period. Independent Advisor Alliance lifted its position in IQVIA by 4.2% in the first quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company's stock worth $318,000 after purchasing an additional 72 shares during the period. Finally, E Fund Management Co. Ltd. lifted its position in shares of IQVIA by 3.7% during the 2nd quarter. E Fund Management Co. Ltd. now owns 2,099 shares of the medical research company's stock valued at $331,000 after acquiring an additional 74 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Up 0.2%

NYSE:IQV opened at $204.25 on Friday. The firm has a market capitalization of $34.72 billion, a PE ratio of 29.56, a price-to-earnings-growth ratio of 2.24 and a beta of 1.32. The stock has a 50 day moving average of $187.74 and a 200-day moving average of $167.57. IQVIA has a 52 week low of $134.65 and a 52 week high of $237.34. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.77 by $0.04. The company had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business's revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the company earned $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Analysts predict that IQVIA will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.